Form 4: Heron Therapeutics EVP Converts RSUs to Common Stock

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 11,695 restricted stock units into common stock.

Summary

• William P. Forbes, Executive Vice President and Chief Development Officer of Heron Therapeutics, Inc. (HRTX), reported a transaction on January 31, 2026.
• Forbes exercised 11,695 Restricted Stock Units (RSUs), resulting in the acquisition of 11,695 shares of common stock.
• Following this conversion, Forbes directly holds 181,773 shares of common stock.
• Forbes also directly holds 140,332 Restricted Stock Units.
• The Restricted Stock Units vest in 16 equal installments, with the vesting schedule commencing one quarter after the grant date of January 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting a routine vesting and conversion of executive equity compensation, which aligns management's interests with shareholders without indicating new operational or financial developments.

Positives

• The conversion of Restricted Stock Units into common stock is a routine vesting event, indicating a standard component of executive compensation.
• Increased direct ownership of common stock by a key executive like William P. Forbes generally aligns management's financial interests with those of shareholders.

Future Outlook

This Form 4 filing reports a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly the exercise and conversion of equity awards like Restricted Stock Units, are standard components of executive compensation packages across publicly traded companies. This event reflects a scheduled vesting and conversion rather than a discretionary open-market purchase or sale, which typically carries different implications for market sentiment.

Comparison to Industry Standards

• This Form 4 filing details a routine executive equity compensation event, which is consistent with corporate governance and compensation practices observed in the biotechnology and pharmaceutical sectors. Companies such as Regeneron Pharmaceuticals or Vertex Pharmaceuticals frequently report similar vesting and conversion activities by their executives as part of their long-term incentive plans.

Related Party Transactions

• The conversion of Restricted Stock Units into common stock by an executive is considered a related-party transaction, as it involves the company and an insider as part of an established compensation agreement.

Stakeholder Impact

• Shareholders: The increased direct ownership by a key executive may be viewed positively as it further aligns management's interests with those of the company's shareholders.
• Employees: This specific filing does not indicate any direct impact on the broader employee base.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction (vesting and conversion of Restricted Stock Units) and does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. It is a standard compensation event.

Keywords

Heron Therapeutics, HRTX, Form 4, Insider Transaction, Restricted Stock Units, Common Stock, William P. Forbes, Executive Compensation, Beneficial Ownership